Omniflow® II biosynthetic graft offers acceptable early and mid-term outcomes in redo surgery in patients with critical limb-threatening ischemia with no available autologous vein material.

Nicola TroisiAnna M SocrateGennaro VigliottiVittorio DorrucciFilippo BenedettoPaolo FrigattiStefano MichelagnoliRaffaella Berchiollinull null

Published in: International angiology : a journal of the International Union of Angiology (2024)

II biosynthetic graft offers acceptable ywo-year outcomes in redo surgery in CLTI patients with no available autologous vein material. Further studies with larger population sizes are needed to validate these outcomes.

Keyphrases

minimally invasive
coronary artery bypass
bone marrow
cell therapy
stem cells
aortic valve replacement
type diabetes
adipose tissue
acute coronary syndrome
insulin resistance
atrial fibrillation